Special Issue "Biomarkers and Immunotherapeutic Targets in Glioblastoma"

A special issue of Biology (ISSN 2079-7737).

Deadline for manuscript submissions: 31 May 2021.

Special Issue Editors

Dr. Jiao Wang
Website
Guest Editor
Purdue College of Pharmacy, Heine Pharmacy Building 575 Stadium Mall Drive West Lafayette, IN 47907-2091
Dr. Sandro Matosevic
Website
Guest Editor
Purdue College of Pharmacy, Heine Pharmacy Building 575 Stadium Mall Drive West Lafayette, IN 47907-2091

Special Issue Information

Glioblastoma, also called GBM, the most aggressive type of primary brain tumor, makes up about 15% of all brain tumors and is projected to be diagnosed in nearly 210,000 people globally each year. Despite aggressive treatment with surgery, radiation, and chemotherapy, GBM remains an incurable tumor with a median survival of only 15 months. Immunotherapy has seen great success in the treatment of various types of cancer, from melanoma to lung, breast, colorectal, kidney, and even some brain cancers. Accordingly, this type of therapy may give us a lot of hope and act as the future of GBM treatment. To date, GBM has not been among immunotherapy success stories yet due to several obstacles including the highly immunosuppressive nature of GBM and the limitations of the immune response in the central nervous system. Currently, a diverse set of biomarkers such as different checkpoint molecules have already been well investigated and implicated as potential immunotherapeutic targets and prognostic indicators in some types of cancers. Therefore, understanding the biomarkers for appropriate patient selection as well as tumor progression are necessary for implementation of immunotherapy for GBM. Additionally, the combination of immune therapies driven by these biomarkers would be the key for the future of immunotherapy for GBM. This Special Issue welcomes the submission of original research and review manuscripts focusing on biomarkers of interest for the diagnosis, therapy, an theranostics of GBM, but also on the specific technologies employed in their identification and targeting, helping us to achieve a realistic overview of this exciting and interdisciplinary field of biomedical research. It is envisioned that this Special Issue will help readers to become more familiar with advances in the discovery and development of effective immunotherapeutic treatments for the devastating GBM.

Dr. Jiao Wang
Dr. Sandro Matosevic
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers

This special issue is now open for submission.
Back to TopTop